butorphanol
Trade name: stadol
Approved
Aug 22, 1978
Butorphanol is a synthetic opioid agonist-antagonist analgesic with a pharmacological and therapeutic profile that has been well established since its launch as a parenteral formulation in 1978. The introduction of a transnasal formulation of butorphanol represents a new and noninvasive presentation of an analgesic for moderate to severe pain. This route of administration bypasses the gastrointestinal tract, and this is an advantage for a drug such as butorphanol that undergoes significant first-pass metabolism after oral administration. The onset of action and systemic bioavailability of butorphanol following transnasal delivery are similar to those after parenteral administration. Butorphanol blocks pain impulses at specific sites in the brain and spinal cord. Butorphanol has agonistic activity at the κ-receptor and antagonistic activity at the μ-receptor. It also exhibits partial agonistic activity at the σ-receptor. — NCATS
Clinical trial activity
17 trials · 16 clinical orgs · 10 marketing orgs
Earliest trial started Jan 1, 2007 (NCT00510666)
Timeline
1970s
- Aug 22, 1978
Bristol-Myers — Earliest FDA Approval
- Aug 22, 1978
Apothecon — NDA Secondary Org
- Aug 22, 1978
Bristol-Myers — NDA Organization
1990s
- Dec 12, 1991
Bristol-Myers Squibb — NDA Secondary Org
- Jan 22, 1997
Hospira — Marketing Organization
- Aug 12, 1998
West-Ward Pharmaceutical — Marketing Organization
2000s
- Aug 8, 2001
Rising Pharmaceuticals — Marketing Organization
- Aug 8, 2001
Mylan — Marketing Organization
- Oct 23, 2001
Baxalta — Marketing Organization
- Dec 4, 2002
Apotex — Marketing Organization
- Apr 29, 2009
Hikma — Marketing Organization
2010s
- Jan 1, 2017
Earliest Phase 2 Sponsor(trial)
Indications
Approved for
Studied for
Mechanism of action
- Kappa opioid receptorPARTIAL AGONIST
OPRK1 partial agonist
- Mu opioid receptorPARTIAL AGONIST
OPRM partial agonist
May be mixed agonist/antagonist
Approval history
- approvedPriority reviewAug 22, 1978
Chemistry & pharmacology
SMILES
Oc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3- Mol. weight
- 327.47 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral, Topical
- Availability
- Prescription Only
Oral
No
Parenteral
Yes
Topical
Yes
Sources
- ChEMBLCHEMBL33986 ↗
- WikipediaButorphanol ↗
- NCATSQV897JC36D ↗
- ChEMBLCHEMBL299400 ↗
Also known as
- (-)-17-(cyclobutylmethyl)morphinan-3,14-diol
- (-)-17-(cyclobutylmethyl)morphinan-3,14-diol
- bc 2627
- bc-2627
- butorfanol
- butorfanol
- butorphanol
- butorphanol
- butorphanol
- butorphanol
- butorphanol
- butorphanol
- butorphanol
- butorphanol
- butorphanol
- butorphanol
- (-)-butorphanol
- (-)-butorphanol
- (-)-butorphanol
- butorphanol tartrate
- butorphanol tartrate
- butorphanol tartrate
- butorphanol tartrate
- butorphanol tartrate
- butorphanolum
- butorphanolum
- levo-bc-2627
- levo-bc-2627
- levo-bc-2627 tartrate
- levo-bc-2627 tartrate
- (-)-n-cyclobutylmethyl-3,14-dihydroxymorphinan
- (-)-n-cyclobutylmethyl-3,14-dihydroxymorphinan
- stadol
- stadol
- stadol
- stadol ns
- stadol ns
- torbugesic
- torbugesic
- torbutrol
- torbutrol
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06031129 | N/A | Mar 1, 2023 | Eastern Hepatobiliary Surgery Hospital, Jinlin University |
| NCT06398834 | Phase 4 | Mar 1, 2022 | Anhui Medical University, Huazhong University of Science and Technology, Second People's Hospital of Hefei City |
| NCT05024799 | Phase 4 | Jan 31, 2022 | Qingdao University |
| NCT05201560 | N/A | Jan 31, 2022 | Fudan University |
| NCT06524596 | N/A | Jan 1, 2022 | Wuhan Children's Hospital |
| NCT04477733 | N/A | Aug 14, 2020 | Capital Medical University |
| NCT04490980 | N/A | Aug 1, 2020 | Huazhong University of Science and Technology |
| NCT04436224 | Phase 4 | Jul 31, 2020 | Southern Medical University |
| NCT04295109 | N/A | Mar 2, 2020 | Nanjing Medical University |
| NCT04315935 | Phase 4 | Dec 15, 2019 | Hebei Medical University, Hengrui Therapeutics, Inc. |
| NCT03429179 | Phase 4 | Dec 1, 2017 | Shengjing Hospital |
| NCT03810391 | Phase 2 | Dec 1, 2017 | Shengjing Hospital |
| NCT03398759 | N/A | Oct 1, 2017 | Jiao Tong University |
| NCT02043366 | N/A | Feb 1, 2014 | Nanjing Medical University, Tianjin Medical University |
| NCT00795314 | Phase 4 | Nov 1, 2008 | Nanjing Medical University |
| NCT00738192 | Phase 4 | Jul 1, 2008 | Nanjing Medical University |
| NCT00510666 | Phase 4 | Jan 1, 2007 | Nanjing Medical University |
Organizations
Research & Development (16)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Nanjing Medical University | Academic/Hospital | 5 | 5 | 2 | 2007 |
| Huazhong University of Science and Technology | Academic/Hospital | 2 | 1 | 2 | 2020 |
| Shengjing Hospital | Academic/Hospital | 2 | 2 | 2 | 2017 |
| Anhui Medical University | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Capital Medical University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Eastern Hepatobiliary Surgery Hospital | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Fudan University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Hebei Medical University | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Hengrui Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2019 |
| Jiao Tong University | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Jinlin University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Qingdao University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Second People's Hospital of Hefei City | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Southern Medical University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Tianjin Medical University | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Wuhan Children's Hospital | Academic/Hospital | 1 | 1 | 1 | 2022 |
Marketing (14)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Apotex | For profit | MKTG | Dec 4, 2002 |
| Apotex | For profit | SYN | Dec 4, 2002 |
| Apothecon | For profit | NDA2 | Aug 22, 1978 |
| Baxalta | For profit | MKTG | Oct 23, 2001 |
| Bristol-Myers | For profit | NDA | Aug 22, 1978 |
| Bristol-Myers Squibb | For profit | NDA2 | Dec 12, 1991 |
| Hikma | For profit | MKTG | Apr 29, 2009 |
| Hikma | For profit | SYN | Mar 12, 2002 |
| Hikma | For profit | SYN | Mar 12, 2002 |
| Hospira | For profit | MKTG | Jan 22, 1997 |
| Mylan | For profit | MKTG | Aug 8, 2001 |
| Rising Pharmaceuticals | For profit | MKTG | Aug 8, 2001 |
| Rising Pharmaceuticals | For profit | SYN | Aug 8, 2001 |
| West-Ward Pharmaceutical | For profit | MKTG | Aug 12, 1998 |